2017 Press Releases

Keyword Search
2017 | 2016 | 2015
02/03/17FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
Higher pamrevlumab exposure associated with improved survival SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label, dose-escalation Phase 1/2 study (FGCL-MC3019-028) of pamrevlumab in pancreatic cancer were published in the Journal of Cancer Clinical Trials (Picozzi et al., J Cancer Clin Trials 2017, 2:123). The published results support a dose-related incr... 
Printer Friendly Version
01/30/17FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
Roxadustat: effective in dialysis (hemodialysis and peritoneal dialysis) and non-dialysis chronic kidney disease (CKD) patients SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today reported positive topline results from the two Phase 3 clinical studies of roxadustat (FG-4592 or 罗沙司他[1]) designed to support new drug application ... 
Printer Friendly Version
01/20/17Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
Promising safety and efficacy observed in open-label, randomized study SAN FRANCISCO, Jan. 20, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) today announced that updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) were presented in a poster session during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco. Pamrevlumab is a fully... 
Printer Friendly Version